Clinical Trial Update: Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the combination of niraparib and dostarlimab for recurrent or persistent endometrial serous carcinoma. The trial is currently active bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Serous Carcinoma

Drugs mentioned

• Dostarlimab (dostarlimab)
• Niraparib (Niraparib)

Snippet

Sponsor: Casey Cosgrove | Conditions: Recurrent Endometrial Serous Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING